Nurix Therapeutics (NRIX) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free NRIX Stock Alerts $15.40 -0.50 (-3.14%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:53 AM | markets.businessinsider.comNurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948May 16 at 5:24 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX)May 16 at 3:30 AM | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Receives New Coverage from Analysts at StephensMay 15 at 5:39 PM | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading Up 6.7%Nurix Therapeutics (NASDAQ:NRIX) Shares Up 6.7%May 15 at 8:41 AM | marketbeat.comNurix Therapeutics' (NRIX) "Buy" Rating Reaffirmed at Stifel NicolausStifel Nicolaus reaffirmed a "buy" rating and set a $27.00 price target on shares of Nurix Therapeutics in a research note on Wednesday.May 14 at 6:14 PM | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)May 14 at 6:14 PM | msn.comStephens & Co. Initiates Coverage of Nurix Therapeutics (NRIX) with Overweight RecommendationMay 14 at 6:14 PM | finance.yahoo.comNurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)May 14 at 1:24 PM | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday.May 14 at 10:00 AM | globenewswire.comNurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)May 14 at 9:39 AM | markets.businessinsider.comKey Takeaways From Nurix Therapeutics Analyst RatingsMay 14 at 8:10 AM | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Earns Overweight Rating from Analysts at StephensStephens started coverage on Nurix Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $20.00 price objective for the company.May 7, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Up 6.6%Nurix Therapeutics (NASDAQ:NRIX) Trading 6.6% HigherMay 7, 2024 | globenewswire.comNurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceMay 6, 2024 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 3, 2024 | insidertrades.comNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 3,499 SharesMay 1, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Stock Price Up 6.4%Nurix Therapeutics (NASDAQ:NRIX) Trading 6.4% HigherMay 1, 2024 | insidertrades.comNurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $16,699.48 in StockApril 25, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading Down 6.9%Nurix Therapeutics (NASDAQ:NRIX) Trading Down 6.9%April 18, 2024 | stockhouse.comNurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesApril 17, 2024 | msn.comNurix Therapeutics (NRIX) Price Target Increased by 5.58% to 25.09April 16, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Down 4.7% Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 4.7%April 15, 2024 | msn.comNurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating ExpectationsApril 15, 2024 | seekingalpha.comNurix Therapeutics Advances Promising Protein Degraders For B-Cell MalignanciesApril 12, 2024 | marketwatch.comShares of Nurix Therapeutics Down 6% on Plans for Stock SaleApril 12, 2024 | seekingalpha.comNurix Therapeutics prices upsized stock offering to raise $175 millionApril 11, 2024 | markets.businessinsider.comNurix Therapeutics Announces $125 Mln Public Stock Offering; Stock Down In After-hoursApril 11, 2024 | globenewswire.comNurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingApril 11, 2024 | globenewswire.comNurix Therapeutics Announces Proposed Public OfferingApril 11, 2024 | marketbeat.comRoyal Bank of Canada Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $23.00Royal Bank of Canada lifted their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Thursday.April 11, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Analyst UpgradeNurix Therapeutics (NASDAQ:NRIX) Shares Gap Up on Analyst UpgradeApril 11, 2024 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from AnalystsNurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommeApril 10, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading Down 7.2%Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 7.2%April 10, 2024 | finanznachrichten.deNurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateApril 10, 2024 | markets.businessinsider.comNurix Therapeutics, Inc. Q1 Loss increases, but beats estimatesApril 10, 2024 | finance.yahoo.comNurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024April 10, 2024 | msn.comNRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024April 10, 2024 | globenewswire.comNurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateApril 9, 2024 | marketwatch.comNurix Therapeutics Shares Climb 19% on Extended Sanofi CollaborationApril 9, 2024 | globenewswire.comNurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesApril 9, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Trading 3.9% Higher Nurix Therapeutics (NASDAQ:NRIX) Stock Price Up 3.9%April 9, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday.April 9, 2024 | globenewswire.comNurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6April 3, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Shares Down 4% Nurix Therapeutics (NASDAQ:NRIX) Trading Down 4%April 3, 2024 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesApril 2, 2024 | markets.businessinsider.comNurix Therapeutics Earns ‘Buy’ Rating on Strong Partnerships and Revenue PotentialApril 2, 2024 | markets.businessinsider.comCritical Insights From Nurix Therapeutics Analyst Ratings: What You Need To KnowApril 2, 2024 | marketbeat.comNurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday.April 2, 2024 | finance.yahoo.comNurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesApril 2, 2024 | markets.businessinsider.comNurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. NRIX Media Mentions By Week NRIX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NRIX News Sentiment▼0.220.55▲Average Medical News Sentiment NRIX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NRIX Articles This Week▼163▲NRIX Articles Average Week Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PAHC News AUPH News PRTC News SAGE News NUVB News WVE News COGT News CVAC News ANAB News PRAX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NRIX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
